


Neratinib ExteNET

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects




Other adjustments



Neratinib ExteNET

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival




Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Extended adjuvant treatment of patients with early-stage hormone receptor-positive HER2-positive breast cancer who completed adjuvant trastuzumab-based therapy
 Experimental Arm: Neratinib
 Control Arm: Placebo

